| APH |
Report |
Q2 2026 revenue |
BEAT |
pred ~$8.43B vs. cons $8.26B |
MEDIUM |
| APH |
Report |
Q2 2026 adjusted diluted EPS |
BEAT |
pred ~$1.22 vs. cons $1.19 |
MEDIUM |
| APH |
Report |
Q2 2026 adjusted operating margin |
BEAT |
pred ~27.7% vs. cons 27.4% |
LOW |
| APH |
Guide |
Q3 2026 revenue |
BETTER |
guide ~$8.80B vs. cons $8.69B (Q3 2026) |
MEDIUM |
| APH |
Guide |
Q3 2026 adjusted diluted EPS |
UNCHANGED |
guide ~$1.30 vs. cons $1.30 (Q3 2026) |
MEDIUM |
| APH |
Return |
Day-1 residual (stock − beta × S&P 500) |
+4.8% |
— |
MEDIUM |
| APH |
Return |
5-day cumulative residual |
+6.3% (FOLLOW-THROUGH) |
Q2 EPS of ~$1.22 vs. $1.19 and Q3 guidance of ~$1.30 vs. $1.30 imply a Q4 EPS hurdle of only ~$1.31 to reach FY2026 consensus of $4.89, supporting modest upward revisions rather than an out-period cut. |
MEDIUM |